Published in Curr Treat Options Neurol on April 01, 2013
Radiotherapy for glioblastoma in the elderly. N Engl J Med (2007) 5.64
Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity. Neurology (2013) 2.59
Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain (2012) 2.39
Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology (2014) 2.38
MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke (2006) 1.91
Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol (2010) 1.49
Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol (2003) 1.47
Acute-onset chorea, dystonia, and cardiac fibroelastoma in a child: a paraneoplastic association? Mov Disord (2012) 1.44
Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain (2010) 1.42
Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain (2002) 1.37
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol (2011) 1.34
In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis (2010) 1.33
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol (2010) 1.28
The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain (2009) 1.26
Regulation of spine development by semaphorin3A through cyclin-dependent kinase 5 phosphorylation of collapsin response mediator protein 1. J Neurosci (2007) 1.25
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol (2010) 1.24
Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci (2004) 1.24
Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis (2004) 1.19
Factors influencing early admission in a French stroke unit. Stroke (2002) 1.16
Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol (2014) 1.13
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res (2012) 1.06
Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. J Neurol (2010) 1.06
Peri-ictal pseudoprogression in patients with brain tumor. Neuro Oncol (2011) 1.06
Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1. J Neurosci (2010) 1.05
Collapsin response mediator protein 1 mediates reelin signaling in cortical neuronal migration. J Neurosci (2006) 1.04
Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. J Neurochem (2006) 1.03
Delayed onset of a second paraneoplastic neurological syndrome in eight patients. J Neurol Neurosurg Psychiatry (2010) 1.02
Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. J Comp Neurol (2005) 1.02
Surface dynamics of GluN2B-NMDA receptors controls plasticity of maturing glutamate synapses. EMBO J (2014) 1.02
Ethical issues of informed consent in acute stroke. Analysis of the modalities of consent in 56 patients enrolled in urgent therapeutic trials. Cerebrovasc Dis (2005) 1.01
Update on paraneoplastic neurological syndromes. Curr Opin Oncol (2009) 0.95
An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients. Mol Cancer (2010) 0.95
Processing and nuclear localization of CRMP2 during brain development induce neurite outgrowth inhibition. J Biol Chem (2008) 0.94
SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One (2012) 0.94
Phosphorylation of CRMP2 (collapsin response mediator protein 2) is involved in proper dendritic field organization. J Neurosci (2012) 0.93
Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. PLoS One (2008) 0.93
Phosphorylation of collapsin response mediator protein 2 on Tyr-479 regulates CXCL12-induced T lymphocyte migration. J Biol Chem (2009) 0.93
CRMP5 interacts with tubulin to inhibit neurite outgrowth, thereby modulating the function of CRMP2. J Neurosci (2010) 0.93
Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiol (2014) 0.92
Collapsin response mediator protein 4a (CRMP4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron axonal degeneration and cell death. J Neurosci (2010) 0.91
Chemotherapy is the cornerstone of the combined surgical treatment of lung cancer with synchronous brain metastases. Lung Cancer (2006) 0.88
Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry (2007) 0.88
In vitro and in vivo models of cerebral ischemia show discrepancy in therapeutic effects of M2 macrophages. PLoS One (2013) 0.88
Expression of collapsin response mediator proteins 1, 2 and 5 is differentially regulated in newly generated and mature neurons of the adult olfactory system. Eur J Neurosci (2005) 0.87
Autoimmune limbic encephalitis: an expanding concept. Lancet Neurol (2009) 0.87
Telomere profiling: toward glioblastoma personalized medicine. Mol Neurobiol (2012) 0.87
Up-front temozolomide in elderly patients with glioblastoma. J Neurooncol (2010) 0.86
VEGF modulates NMDA receptors activity in cerebellar granule cells through Src-family kinases before synapse formation. Proc Natl Acad Sci U S A (2011) 0.86
Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab (2003) 0.86
Ipsilateral ptosis as main feature of tuberothalamic artery infarction. Neurol Sci (2009) 0.86
New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary (2012) 0.85
Expression of the onconeural CV2/CRMP5 antigen in thymus and thymoma. J Neuroimmunol (2006) 0.85
Acute headache followed by focal neuropsychological impairment in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). J Stroke Cerebrovasc Dis (2010) 0.85
Early-stage investigations of ultrasmall superparamagnetic iron oxide-induced signal change after permanent middle cerebral artery occlusion in mice. Stroke (2009) 0.85
G303V tau mutation presenting with progressive supranuclear palsy-like features. Mov Disord (2011) 0.84
Extensive myelitis associated with anti-NMDA receptor antibodies. BMC Neurol (2013) 0.84
Transient alterations in granule cell proliferation, apoptosis and migration in postnatal developing cerebellum of CRMP1-/- mice. Genes Cells (2006) 0.83
ATAD3B is a human embryonic stem cell specific mitochondrial protein, re-expressed in cancer cells, that functions as dominant negative for the ubiquitous ATAD3A. Mitochondrion (2012) 0.83
HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes. J Neuroimmunol (2010) 0.82
CRMP5 regulates generation and survival of newborn neurons in olfactory and hippocampal neurogenic areas of the adult mouse brain. PLoS One (2011) 0.82
Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. J Neurooncol (2015) 0.81
Extensive expression of collapsin response mediator protein 5 (CRMP5) is a specific marker of high-grade lung neuroendocrine carcinoma. Am J Surg Pathol (2008) 0.81
Mapping and kinetics of microglia/neuron cell-to-cell contacts in the 6-OHDA murine model of Parkinson's disease. Glia (2013) 0.81
Monoclonal antibodies to 65kDa glutamate decarboxylase induce epitope specific effects on motor and cognitive functions in rats. Orphanet J Rare Dis (2013) 0.81
NG2-expressing glial precursor cells are a new potential oligodendroglioma cell initiating population in N-ethyl-N-nitrosourea-induced gliomagenesis. Carcinogenesis (2010) 0.81
Full recovery of agrypnia associated with anti-Lgi1 antibodies encephalitis under immunomodulatory treatment: a case report with sequential polysomnographic assessment. Sleep Med (2012) 0.81
Pp IX silica nanoparticles demonstrate differential interactions with in vitro tumor cell lines and in vivo mouse models of human cancers. Photochem Photobiol (2009) 0.80
Is autoimmune limbic encephalitis a channelopathy? Lancet Neurol (2010) 0.79
Altered expression of CRMPs in the brain of bovine spongiform encephalopathy-infected mice during disease progression. Brain Res (2009) 0.79
Collapsin response mediator protein 5 (CRMP5) induces mitophagy, thereby regulating mitochondrion numbers in dendrites. J Biol Chem (2013) 0.79
Syk kinase is phosphorylated in specific areas of the developing nervous system. Neurosci Res (2011) 0.78
Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis. J Neurol (2010) 0.77
Collapsin response-mediator protein 5 (CRMP5) phosphorylation at threonine 516 regulates neurite outgrowth inhibition. Eur J Neurosci (2014) 0.77
Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications. Ther Adv Neurol Disord (2010) 0.77
PET follow-up in a case of anti-NMDAR encephalitis: arguments for cingulate limbic encephalitis. Epileptic Disord (2012) 0.76
Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation. Exp Cell Res (2013) 0.76
The collapsin response mediator protein 5 onconeural protein is expressed in Schwann cells under axonal signals and regulates axon-Schwann cell interactions. J Neuropathol Exp Neurol (2012) 0.76
From anti-GAD to ataxia with ocular motor apraxia type 2: through the looking glass. J Neurol (2013) 0.75
[Neurological complications of cancer]. Rev Prat (2003) 0.75
Simultaneous subarachnoid hemorrhage and cerebellar infarct revealing vertebral artery aneurysm: acute magnetic resonance imaging assessment. Arch Neurol (2005) 0.75
Magnetic resonance imaging: significance of early ischemic changes on computed tomography. Cerebrovasc Dis (2004) 0.75
[What type of adjuvant chemotherapy should be proposed for the initial treatment of glioblastoma?]. Presse Med (2007) 0.75
[Limbic encephalitis. A misdiagnosed syndrome]. Psychol Neuropsychiatr Vieil (2008) 0.75
Abnormal expression of truncated CRMP-1 protein in the brain cortex of MPSIIIB mice. Mol Genet Metab (2008) 0.75
[Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions]. Bull Acad Natl Med (2014) 0.75
The workflow from post-mortem human brain sampling to cell microdissection: a Brain Net Europe study. J Neural Transm (Vienna) (2015) 0.75
[Brain metastases: epidemiology, diagnosis and imaging]. Rev Prat (2014) 0.75